HONG KONG – China has for several years stood out as the major emerging market for multinational pharmaceutical companies, and it will likely continue to do so with deeper, widespread reform expected to improve the pharmaceutical and health care industry in the near future.
HONG KONG –Tensions have been building in India's pharmaceutical sector as it tries to resolve a tricky dilemma. Stronger intellectual property (IP) protection is needed to sustain the country's rapid economic growth, but that may come at the expense of affordable health care.
HONG KONG – China has for several years stood out as the major emerging market for multinational pharmaceutical companies, and it will likely continue to do so with deeper, widespread reform expected to improve the pharmaceutical and health care industry in the near future.
HONG KONG – Tensions have been building in India’s pharmaceutical sector as it tries to resolve a tricky dilemma. Stronger intellectual property (IP) protection is needed to sustain the country’s rapid economic growth, but that may come at the expense of affordable health care.
HONG KONG – In the wake of the Indian patent office granting U.S. pharmaceutical giant Pfizer Inc. a patent for its pneumococcal conjugate vaccine (PCV), hopes have been dashed for better access to an affordable vaccine against pneumonia in the developing country of more than 1.3 billion people.
HONG KONG – In the wake of the Indian patent office granting U.S. pharmaceutical giant Pfizer Inc. a patent for its pneumococcal conjugate vaccine (PCV), hopes have been dashed for better access to an affordable vaccine against pneumonia in the developing country of more than 1.3 billion people.
HONG KONG – As the incidence of diabetes in China continues to climb to alarming rates, multinational and local pharmaceutical companies are racing to take a larger slice of the growing market pie, but patients in lower-tier cities will have to wait before they can access innovative treatments.
HONG KONG – As the incidence of diabetes in China continues to climb to alarming rates, multinational and local pharmaceutical companies are racing to take a larger slice of the growing market pie, but patients in lower-tier cities will have to wait before they can access innovative treatments.
